Welcome to our dedicated page for Hoth Therapeutics news (Ticker: HOTH), a resource for investors and traders seeking the latest updates and insights on Hoth Therapeutics stock.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for dermatological disorders and other significant medical needs. The company focuses on conditions such as eczema, chronic wounds, psoriasis, asthma, and acne. Utilizing their proprietary BioLexa Platform, Hoth Therapeutics aims to create two topical cream products to treat eczema and reduce post-procedure infections in aesthetic dermatology patients.
Hoth Therapeutics has established numerous license and partnership agreements with prestigious institutions including The George Washington University, The University of Maryland Baltimore, Isoprene Pharmaceuticals, Inc., North Carolina State University, Chelexa Biosciences, Inc., The University of Cincinnati, and Zyla Therapeutics, Inc. Notably, Hoth is co-developing a topical treatment with Zyla Therapeutics for cutaneous lupus erythematosus, an autoimmune disease that severely impacts patient quality of life.
The company’s research collaborations extend to various areas including HT-001, a potential treatment for cancer patients experiencing skin toxicities from Epidermal Growth Factor Receptor Inhibitors (EGFRI). Hoth has recently received FDA clearance to proceed with protocol amendments in its ongoing Phase 2a clinical trials for HT-001, aiming to optimize clinical outcomes.
Hoth Therapeutics has also made strides in Alzheimer's Disease research with its HT-ALZ project, targeting neuroinflammation and cognitive deficits by antagonizing the NK1 receptor. Pre-clinical research has shown promising results in improving cognitive functions among Alzheimer's patients.
In addition to their pipeline, Hoth's subsidiary Merveille.ai has been pivotal in advancing obesity treatment using artificial intelligence. The discovery of a promising new therapeutic candidate for obesity, leveraging large language model technologies, underscores their commitment to innovative health solutions.
Financially, Hoth Therapeutics recently engaged in an agreement to exercise warrants, raising approximately $4.2 million to support its working capital needs. Their strategic partnership with Venable, LLP further strengthens their intellectual property protection, vital for ongoing and future therapeutic developments.
Collaborations with Wise Systems International SRL and integration of the Nvidia BioNeMo AI platform are set to enhance Hoth's drug discovery capabilities, leveraging artificial intelligence for cutting-edge therapeutic advancements.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced the granting of U.S. Patent No. 10,793,525 for novel 13-Cis-RAMBA retinamides aimed at targeting cancer-associated signaling pathways. This first-of-its-kind patent expires on October 5, 2036. The compounds are designed to disrupt the MNK1/2-driven signaling pathway linked to various cancers, including breast and prostate cancer. Hoth's CEO, Robb Knie, emphasized the patent's contribution to their diverse intellectual property portfolio, which supports continued development in oncology and dermatology therapeutics.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) reported progress on its HT-003 acne treatment, demonstrating the ability to inhibit toll-like receptor 2 (TLR2) gene expression in human keratinocytes, crucial for acne pathophysiology. The research led by Dr. Jonathan Zippin showed no toxicity at doses up to 50 µM. Future testing will focus on determining the minimal effective dose and studying HT-003's broader applications for inflammatory diseases. Hoth aims to enhance life quality for patients with dermatological disorders through innovative therapies.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) has entered a Sponsored Research Agreement with George Washington University to develop a rapid diagnostic device for SARS-CoV-2. This mobile testing solution aims to provide immediate COVID-19 test results using a plasmonic system, allowing patients to detect the virus anywhere. The device has potential for significant public health impact by streamlining testing processes. Initial discussions with the FDA regarding emergency use authorization are planned for early 2021.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced that Dr. Stefanie Johns will join as Chief Scientific Officer and appears on One America News Network on September 1, 2020, at 3:00 PM ET. Dr. Johns will discuss Hoth's recent licensing of a real-time, breath-based COVID-19 mobile testing device. Hoth is a clinical-stage biopharmaceutical company focusing on therapies for dermatological disorders and has entered agreements for developing two vaccine prospects related to COVID-19.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced the appointment of Stefanie Johns, Ph.D., as Chief Scientific Officer, effective September 2020. Dr. Johns has over 8 years of experience in the biopharmaceutical and medical device sectors, having previously worked as Director of Regulatory Affairs at Enable Injections, Inc. She is expected to enhance Hoth's pipeline, particularly the pipeline slated for clinical trials in Q4 2020.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced its CEO, Robb Knie, will present at three investor conferences in September 2020. These events include the LD 500 Virtual Investor Conference on September 3 at 12:20 p.m. ET, the H.C. Wainwright & Co. 22nd Annual Global Investment Conference on September 16 at 1:30 p.m. ET, and the Sidoti & Company 2020 Fall Virtual Investor Conference on September 23 at 2:30 p.m. ET. Management will also be available for one-on-one meetings with investors during these events.
Hoth Therapeutics (NASDAQ: HOTH) updated shareholders on its COVID-19 initiatives and dermatological therapies. The company is advancing its pipeline, including the BioLexa platform for atopic dermatitis, and submitted for ethics board approval in Australia for clinical trials. Hoth licensed VNLG-152 for dermatological diseases and partnered with George Washington University to explore WEG-232 for Erlotinib side effects. Notably, Hoth is developing a breath-based COVID-19 testing device and a self-assembling vaccine platform, with preclinical testing underway.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) has submitted an ethics approval request to the Bellberry Human Research Ethics Committee in Australia for its upcoming clinical study of BioLexa, aimed at treating atopic dermatitis. The study will be a randomized, double-blind, vehicle-controlled trial assessing the safety, tolerability, pharmacokinetics, and efficacy of BioLexa in patients with mild to moderate atopic dermatitis. This marks a significant step in Hoth's clinical development program, as stated by CEO Robb Knie, highlighting the company's commitment to advancing innovative therapies.
Hoth Therapeutics, Inc. (NASDAQ:HOTH) announced its participation in LD Micro's Zooming with LD on August 11, 2020, at 8 AM PDT. CEO Robb Knie will present an overview of the company's operations and recent advancements, particularly the development of a breath-based COVID-19 mobile testing device. This virtual presentation marks an important opportunity for Hoth to showcase its innovations in biopharmaceuticals, especially in treating dermatological disorders and COVID-19 vaccine development. For access, use the password HOTHwithLD.
Hoth Therapeutics, Inc. (NASDAQ:HOTH) will present at LD Micro's Zooming with LD on August 11, 2020. CEO Robb Knie will discuss the company's recent developments, including a license for a breath-based COVID-19 testing device. The presentation is set for 8 AM PDT and will take place virtually via Zoom, accessible with the password HOTHwithLD. Hoth Therapeutics is focused on developing innovative therapies for dermatological conditions and is also advancing two COVID-19 vaccine prospects.
FAQ
What is the current stock price of Hoth Therapeutics (HOTH)?
What is the market cap of Hoth Therapeutics (HOTH)?
What is Hoth Therapeutics, Inc.?
What conditions does Hoth Therapeutics focus on?
What is the BioLexa Platform?
Who are some of Hoth Therapeutics' partners?
What is HT-001?
What recent advancements have been made in Alzheimer's Disease research by Hoth Therapeutics?
How is Hoth Therapeutics advancing obesity treatment?
What financial actions has Hoth Therapeutics recently taken?
What is the significance of Hoth Therapeutics' partnership with Venable, LLP?
How is artificial intelligence being used by Hoth Therapeutics?
